biological source
rabbit
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
SP187, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (113R-14), vial of 0.5 mL concentrate (113R-15), bottle of 1.0 mL predilute (113R-17), vial of 1.0 mL concentrate (113R-16), bottle of 7.0 mL predilute (113R-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
isotype
IgG
control
liver
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic, membranous
Gene Information
human ... ANPEP(290)
General description
CD13 (aminopeptidase-N) is a transmembrane protease present in many tissues and cell types (e.g., endothelial and epithelial cells, fibroblasts, and leukocytes). CD13 is overexpressed in various solid and hematological malignancies in humans, including acute myeloid leukemia (AML), and is thought to influence tumor progression. Acute promyelocytic leukemia, hypogranular variant, poses difficulties in morphologic interpretation for separation from other subtypes of AML. CD13 is overexpressed in the tumor and is useful in diagnosing this variant by using a panel including antibodies against CD13(+), CD34(+), CD117(+), CD16(-), and CD33(+). Myeloid sarcoma (also called chloroma, extramedullary sarcoma, or granulocytic sarcoma) is essentially a solid tumor composed of myeloblasts or immature myeloid cells in an extramedullary site. It can be isolated or occur during the course of AML, chronic myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasias. Myeloid sarcoma should be distinguished from large cell lymphoma, lymphoblastic lymphoma, Burkitt lymphoma, undifferentiated carcinoma, malignant melanoma, extra-medullary hematopoiesis, and inflammation. Immunochemical analyses are needed for the accurate diagnosis of myeloid sarcoma. CD13 is overexpressed in myeloid sarcoma and anti-CD13 is very useful in diagnosing myeloid sarcoma using a panel including antibodies against CD34, CD43, CD117, MPO, lysozyme, CD163 and CD68. It has been reported that CD13 is expressed in both normal and neoplastic liver tissue, where it exhibits a canalicular distribution pattern similar to that seen for polyclonal CEA and CD10. Thus, anti-CD13 can be useful as an additional marker in differentiating between HCC and non-hepatocellular neoplasms.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
![]() IVD | ![]() IVD | ![]() IVD | ![]() RUO |
Other Notes
CD13 Positive Control Slides, Product No. 113S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 113R-16 | 0841683123538 |
| 113R-14 | 0841683123514 |
| 113R-18 | 0841683123552 |
| 113R-17 | 0841683123545 |
| 113R-15 | 0841683123521 |



